Nanoview Biosciences, Inc.
Doing business as Nanoview Diagnostics
- UEI
- FDRMM8ZJGKK8
- CAGE
- 8HPD9, 7EBE8
- Primary NAICS
- 541713 Research and Development in Nanotechnology
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Nichd - exoview R200 instrument | National Institute of Child Health and Human Development | $166,762 | |
| Exoview R100 automated imager | National Institute on Drug Abuse | $122,743 | |
| Nanoview biosciences exoview R100 | Food and Drug Administration | $140,460 | |
| Single vesicle phenotyping of circulating exosomes carrying immunomodulatory markers for therapy selection and… | National Cancer Institute | $834,051 | |
| Laboratory testing | National Cancer Institute | $19,300 |
About Nanoview Biosciences, Inc.
Nanoview Biosciences, Inc., doing business as Nanoview Diagnostics, is a for-profit corporate entity that provides goods and services to the U.S. federal government through contract and grant awards.
Nanoview has received four past prime federal contract awards to provide testing services and specialized imaging equipment to the Department of Health and Human Services, including the National Institutes of Health and Food and Drug Administration. These contracts were awarded between 2020-2022, with no set-aside designations except one small business set-aside award from the FDA for $147,820.
Nanoview has received one past federal grant award for $834,051 from the National Cancer Institute in 2021 to research and develop a novel assay using Nanoview's technology to identify and quantify circulating exosomes carrying the PD-L1 biomarker. This research project aims to create a predictive diagnostic test for immunotherapy treatment selection and monitoring in non-small cell lung cancer patients.
Quick answers
What is Nanoview Biosciences, Inc.'s UEI?
Nanoview Biosciences, Inc.'s Unique Entity ID (UEI) in SAM.gov is FDRMM8ZJGKK8.
What are Nanoview Biosciences, Inc.'s CAGE codes?
Nanoview Biosciences, Inc.'s CAGE codes are 8HPD9 and 7EBE8.
What is Nanoview Biosciences, Inc.'s primary NAICS code?
Nanoview Biosciences, Inc.'s primary NAICS code is 541713 (Research and Development in Nanotechnology).
Is Nanoview Biosciences, Inc. registered in SAM.gov?
Nanoview Biosciences, Inc.'s SAM.gov registration expired on November 10, 2022.
What is Nanoview Biosciences, Inc.'s most recent federal award?
Nanoview Biosciences, Inc.'s most recent federal contract award is Nichd - exoview R200 instrument (75N94022P00473), from National Institute of Child Health and Human Development, on June 28, 2022.
On GovTribe
See Nanoview Biosciences, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors